Literature DB >> 28534136

Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas.

Masakazu Hashimoto1, Hirotaka Tashiro2, Tsuyoshi Kobayashi1, Shintaro Kuroda1, Michinori Hamaoka1, Hideki Ohdan1.   

Abstract

PURPOSE: Although obesity is associated with hepatocellular carcinoma (HCC) development, its impact on the surgical outcomes of patients with hepatitis B virus (HBV)-and hepatitis C virus (HCV)-related HCC remains unclear.
METHODS: We retrospectively analyzed 714 patients with HCC who underwent curative hepatectomy. Among them, the HBV-related HCC group (n = 125) and HCV-related HCC group (n = 426) were subdivided according to the presence of body mass index (BMI) ≥ 25 kg/m2. The surgical outcomes were compared.
RESULTS: The 5-year overall survival rate after hepatectomy in the HBV-related HCC group was significantly better than that in the HCV-related HCC group. The 5-year overall survival rates of the HBV-related HCC with and without BMI ≥ 25 kg/m2 groups were 65 and 85%, respectively. The 5-year overall survival rates in the HCV-related HCC with and without BMI ≥ 25 kg/m2 groups were 75 and 65%, respectively. The HBV-related HCC with BMI ≥ 25 kg/m2 groups had a significantly worse prognosis than the HBV-related HCC without BMI ≥ 25 kg/m2 groups, while the HCV-related HCC with BMI ≥ 25 kg/m2 groups had a significantly better prognosis than the HCV-related HCC without BMI ≥ 25 kg/m2 groups. Multivariate analysis revealed that BMI ≥ 25 kg/m2 was the positive and negative prognostic factor for the surgical outcomes of patients with HBV- and HCV-related HCC, respectively.
CONCLUSIONS: BMI ≥ 25 kg/m2 negatively affected the surgical outcomes of patients with HBV-related HCC and positively affected those of patients with HCV-related HCC.

Entities:  

Keywords:  Body mass index (BMI); Overweight; Patients with HBV-related HCC; Patients with HCV-related HCC; Prognosis

Mesh:

Year:  2017        PMID: 28534136     DOI: 10.1007/s00423-017-1589-2

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   3.445


  44 in total

1.  Appropriate BMI for Asian populations.

Authors:  Kuninori Shiwaku; Erdembileg Anuurad; Byambaa Enkhmaa; Keiko Kitajima; Yosuke Yamane
Journal:  Lancet       Date:  2004-03-27       Impact factor: 79.321

2.  Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.

Authors:  Yasutoshi Muto; Shunichi Sato; Akiharu Watanabe; Hisataka Moriwaki; Kazuyuki Suzuki; Akinobu Kato; Masahiko Kato; Teiji Nakamura; Kiyohiro Higuchi; Shuhei Nishiguchi; Hiromitsu Kumada
Journal:  Clin Gastroenterol Hepatol       Date:  2005-07       Impact factor: 11.382

3.  Prognostic impact of underlying liver fibrosis and cirrhosis after curative resection of hepatocellular carcinoma.

Authors:  Peter Gassmann; Tilmann Spieker; Joerg Haier; Fabian Schmidt; Wolf Arif Mardin; Norbert Senninger
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

4.  Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma.

Authors:  Hiroki Nishikawa; Yukio Osaki; Haruhiko Takeda; Azusa Sakamoto; Sumio Saito; Norihiro Nishijima; Akihiro Nasu; Akira Arimoto; Ryuichi Kita; Toru Kimura
Journal:  J Gastrointestin Liver Dis       Date:  2013-06       Impact factor: 2.008

5.  ESPEN Guidelines on Enteral Nutrition: Liver disease.

Authors:  M Plauth; E Cabré; O Riggio; M Assis-Camilo; M Pirlich; J Kondrup; P Ferenci; E Holm; S Vom Dahl; M J Müller; W Nolte
Journal:  Clin Nutr       Date:  2006-05-16       Impact factor: 7.324

6.  Estimating progression to cirrhosis in chronic hepatitis C virus infection.

Authors:  A J Freeman; G J Dore; M G Law; M Thorpe; J Von Overbeck; A R Lloyd; G Marinos; J M Kaldor
Journal:  Hepatology       Date:  2001-10       Impact factor: 17.425

Review 7.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

8.  Flow cytometric DNA analysis of cirrhotic liver cells in patients with hepatocellular carcinoma can provide a new prognostic factor.

Authors:  S Ruà; A Comino; A Fruttero; P Torchio; H Bouzari; S Taraglio; B Torchio; L Capussotti
Journal:  Cancer       Date:  1996-09-15       Impact factor: 6.860

Review 9.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

10.  Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort.

Authors:  Dong Hyun Sinn; Geum-Youn Gwak; Juhee Cho; Seung Woon Paik; Byung Chul Yoo
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

View more
  7 in total

Review 1.  Hepatocellular Carcinoma: Etiology and Current and Future Drugs.

Authors:  Aastha Jindal; Anusha Thadi; Kunwar Shailubhai
Journal:  J Clin Exp Hepatol       Date:  2019-01-25

2.  Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.

Authors:  Lu-Shan Xiao; Rui-Ning Li; Hao Cui; Chang Hong; Chao-Yi Huang; Qi-Mei Li; Cheng-Yi Hu; Zhong-Yi Dong; Hong-Bo Zhu; Li Liu
Journal:  BMC Cancer       Date:  2022-07-06       Impact factor: 4.638

3.  Occult HBV infection status and its impact on surgical outcomes in patients with curative resection for HCV-associated hepatocellular carcinoma.

Authors:  Koutaro Yamaji; Keita Kai; Sho Komukai; Hiroki Koga; Takao Ide; Atsushi Kawaguchi; Hirokazu Noshiro; Shinichi Aishima
Journal:  Hepatobiliary Surg Nutr       Date:  2018-12       Impact factor: 7.293

4.  Development and validation of a nomogram for assessing survival in patients with hepatocellular carcinoma after hepatectomy.

Authors:  Rong-Rui Huo; Xu Liu; Jing Cui; Liang Ma; Kun-Hua Huang; Cai-Yi He; Yang Yang; Xue-Mei You; Wei-Ping Yuan; Bang-De Xiang; Jian-Hong Zhong; Le-Qun Li
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

Review 5.  The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.

Authors:  Mai-Huong Thi Ngo; Han-Yin Jeng; Yung-Che Kuo; Josephine Diony Nanda; Ageng Brahmadhi; Thai-Yen Ling; Te-Sheng Chang; Yen-Hua Huang
Journal:  Int J Mol Sci       Date:  2021-02-16       Impact factor: 5.923

6.  A Novel Nomogram Model to Predict the Recurrence-Free Survival and Overall Survival of Hepatocellular Carcinoma.

Authors:  Shu-Wen Zhang; Ning-Ning Zhang; Wen-Wen Zhu; Tian Liu; Jia-Yu Lv; Wen-Tao Jiang; Ya-Min Zhang; Tian-Qiang Song; Li Zhang; Yan Xie; Yong-He Zhou; Wei Lu
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

7.  Association of β-cell function and cognitive impairment in patients with abnormal glucose metabolism.

Authors:  Mengyi Guo; Jiaokun Jia; Jia Zhang; Mingyue Zhou; Anxin Wang; Shengyun Chen; Xingquan Zhao
Journal:  BMC Neurol       Date:  2022-06-23       Impact factor: 2.903

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.